

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-330 / S-017

ADMINISTRATIVE DOCUMENTS
AND
CORRESPONDENCE



NDA 20-330/S-017

CBE-0 SUPPLEMENT

Merck & Co., Inc.
Attention: Virginia G. Snyder
Manager, Regulatory Affairs
P.O. Box 4
Sumneytown Pike, BLA-20
West Point, PA 19486

Dear Ms. Snyder:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Timoptic XE (timolol maleate ophthalmic gel forming solution) 0.25%, 0.5%

NDA Number: 20-330

Supplement Number: S-017

Date of Supplement: June 20, 2003

Date of Receipt: June 23, 2003

This supplemental application, submitted as a "Supplement - Changes Being Effected" supplement, proposes revisions to the HOW SUPPLIED and DESCRIPTION sections of the labeling.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on August 22, 2003, in accordance with 21 CFR 314.101(a).

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be

addressed as follows:

U.S. Postal Service:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anti-Inflammatory, Analgesic
and Ophthalmic Drug Products, HFD-550
5600 Fishers Lane
Rockville, Maryland 20857

Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Anti-Inflammatory, Analgesic
and Ophthalmic Drug Products, HFD-550
9201 Corporate Boulevard
Rockville, Maryland 20850-3202

If you have any questions, call Michael Puglisi, Project Manager, at (301) 827-2090.

Sincerely,

{See appended electronic signature page}

Carmen DeBellas, R.Ph.
Chief, Project Management Staff
Division of Anti-Inflammatory, Analgesic
and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Michael Puglisi
7/7/03 11:58:51 AM
for Carmen DeBellas